Helsinn Will Present at the 26th Annual J.P. Morgan Healthcare Conference, San
Francisco
LUGANO, Switzerland, December 18 /PRNewswire/ -- Helsinn Healthcare S.A.
today announced that its CEO, Dr. Riccardo Braglia will attend the 26th
Annual J.P. Morgan Healthcare Conference in San Francisco, US, and present an
overview of the Helsinn group, of its products and its corporate goals on
January 9, 2008 at 10:30am local time (6.30pm GMT, 7:30pm Swiss time).
About Helsinn Healthcare
Helsinn is a privately owned pharmaceutical group with headquarters in
Switzerland. Helsinn's core business is the licensing of pharmaceuticals in
therapeutic areas (oncology, cancer supportive care, pain and inflammation,
gastrointestinal).
The company's business strategy is to in-license early-stage new chemical
entities and to complete their development from the performance of
pre-clinical/clinical studies and CMC development to the attainment of market
approvals in strategic markets (U.S. and Europe). Helsinn's products are
eventually out-licensed to its worldwide consolidated network of partners for
distribution. Helsinn's key products in the US are Aloxi(R) (palonosetron)
distributed by MGI Pharma and Gelclair(R) distributed by EKR Therapeutics
Inc., US. The active pharmaceutical ingredients and the drug products are
manufactured at Helsinn's cGMP facilities and supplied worldwide to its
customers. Helsinn's chemical business focuses on the pharmaceutical chemical
process development and manufacturing of advanced intermediates, Active
Pharmaceutical Ingredients (APIs) and High Potency Active Ingredients (HPAIs)
for both the Helsinn group and its outsourcing partners. For more information
about Helsinn, please visit http://www.helsinn.com
Helsinn Healthcare Contact:
Alessandro Bossi, D.V.M.
Director, Business Development
Phone: +41-91-985-21-21
E-Mail: ba@helsinn.com
SOURCE Helsinn Healthcare SA
Helsinn Healthcare Contact: Alessandro Bossi, D.V.M., Director, Business
Development, Phone: +41-91-985-21-21, E-Mail: ba@helsinn.com
